East Genomics provides whole genome sequencing and targeted testing for cancers in line with the National Test Directory for Cancer, for patients across the East Midlands and East of England.
View the current national genomic test directory
Solid tumour (or acquired cancer) tests are provided to inform diagnosis and prognosis across cancer types. They may also reveal gene variants that indicate suitability for targeted therapies.
Cancer testing is funded centrally by NHSE. Referring Trusts are not charged for these services when referred to their designated GLH (View the East Genomics catchment area).
Ordering a test
Standard testing - non-whole genome sequencing
Our standard test order form (non-WGS) can be used for most requests. To avoid unnecessary delays or possible sample rejection, please ensure you are familiar with our referral requirements (included below the order form) and specimen requirements.
Please ensure that you include a clinical indication associated directory test code (M number) when referring for tests.
M numbers and details of gene targets included in each test can be found in the national genomic test directory. All the gene targets listed for the clinical indication tested will be analysed. Only pertinent findings will be reported in the final report.
We aim to ensure that results are delivered within clinically appropriate turn-around times to maximise the potential benefit for patients.
Germline testing
Germline tests for certain familial (inherited) cancer genes are available for patients with a family history via referral from a clinical genetics team. Find out how to request germline testing for inherited cancers.
Germline testing of DPYD is also available to inform toxicity to anti-tumour chemotherapeutics. Information about this test is available here.
Whole genome sequencing
If you require a whole genome sequencing (WGS) test, please refer to our whole genome sequencing page for further information on the process and necessary training prior to your first referral.